The National CDC Bureau came out of nowhere, and the curtain was raised on the public health reform
Some time ago, the Ministry of Human Resources and Social Security issued an announcement, the State Council appointed Wang He Sheng as director of the National Bureau of Disease Control and Prevention, Chang Jile, Shen Hongbing, Sun Yang as deputy director of the National Bureau of Disease Control and Prevention, this "secret action" will be the fourth adjustment of the central-level CDC agencies.
According to related news, the newly established National Bureau of Disease Control and Prevention, will aggregate the former National Health Commission set up within the Bureau of Disease Control and Prevention, Emergency Response Office, Health and Health Supervision Center and other departments, as well as the China Center for Disease Control and Prevention. After the new crown epidemic test, the problems exposed in the field of public health have also attracted the attention of the central government and the hand, the strong establishment of the National Bureau of Disease Control and Prevention, also announced that the depth of reform in the field of public health in China has also kicked off, and how to carry out a bold "correction" under the premise of strict control of the epidemic, has also become the focus of industry The focus of attention is on how to make drastic "corrections" while strictly controlling the epidemic.
Looking for chemical products? Let suppliers reach out to you!
2026-06-22
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Biocytogen announces the launch of the 'Nano 100 Project' to develop fully human therapeutic nanobodies against 100+ targets
-
Wantai Biotech 20-valent pneumonia vaccine started clinical trials, how far is domestic substitution?
-
Yiming Cell 'Suspension 293XS Cell Bank' completed DMF filing with the US FDA
-
The phase III clinical study of Junshi Biologics in combination with teripulimab in the treatment of advanced triple-negative breast cancer reached the primary endpoint
-
The next bombshell: 'PD-1 + ADC', Kelun, Hengrui are going to win numbness?
-
L-Rotator Biotech completed its pre-A financing and continued to increase its investment in the CGT field
-
Hainan to promote drug import facilitation
-
Enable the 'export of EU APIcertification documents' and 'pharmaceutical export salescertificate' electronic proof
-
China to focus on building quality and efficient TCM service system in next five years
Recommend Reading
-
India Raises Cancer Drug Price Caps by 50%
-
Pfizer Warns Germany Over Drug-Pricing Policy
-
Roche Keeps German Diagnostics Investment
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Costs Decline, DOP Prices Retreat from High Levels This Week
-
APVMA Suspends Dimethoate Use on Select Berries Amid Updated Exposure Assessment
-
Wanhua Resumes PO Production: How Much Can Polyether Producers Save on Costs?
-
Recent Formic Acid Market Shows "Decreased Volume, Stable Prices" Trend in China
-
Canada Proposes Revised Maximum Residue Limits for Pyrethrins and Penthiopyrad